This is just to say
I have again
done the thing
where I have said yes
to too much
and which
it would have been better
to say no
forgive me
because everything is
so sweet
and so cool
I recently sat down with my friend and communication guru, @tferriss.
We decided to record a hybrid between one of our brainstorming sessions and also a discussion about the future of biomedicine.
Not surprising, we talked about the rising role of both technology and China.
Patient-first, America-first: The Case For Global Collaboration.
While the rise of Chinese biopharma in the past decade has been meteoric, I’m firmly in the camp that their engagement in the global ecosystem is good for the sector – its more opportunity than threat, great for patients, and is a healthy forcing function to raise the game for everyone
New blog link 👇
We're running a @CompoundVC Research Day on BioML Frontiers in SF on June 23.
Not only are we seeing new model architectures, net new data sources, but we're also seeing new ambitions of BioML from:
- generating de novo viruses
- to making fully fledged human tissues
- to creating foundation model companies from consumer diagnostic data
We've written extensively about this previously and to further our work at Compound in creating legibility of new futures, business models, and progress, we're excited to showcase and host those at the BioML Frontier.
Please join us for a morning of rapid-fire presentations, dreaming, and downright impressive hillclimbs.
We have a couple spots open for speakers if being on the BioML Frontier resonates with you and your team.
(Link below for registration. This will be a small, curated event.)
Thanks to @runwayml for hosting this event at your space!
holy shit I am personally responsible for about as many people moving to SF this year than the entire city built housing units for
absolute embarrassment
FUNDING OPPORTUNITY: @NSF just relaunched SBIR/STTR with $250M. If you’re building high tech and not applying, you’re leaving non-dilutive capital on the table.
Key dates:
- Project Pitch portal opens June 2
- First full proposal deadline: July 27
•Phase I award: up to $305K
•Phase II award: up to $1.25M
•Fast-Track: up to $1.55M
No equity. No investors. Just federal funding for founders doing real R&D.
Apply here → https://t.co/5dhvlgfVYp
1/ US biotech is in crisis, right before AI should be saving millions.
China is stealing away our industry and has surpassed the US in blockbuster pharma deals.
The next FDA Commissioner must be a fighter, and have a plan to overhaul the agency, beat China, and unleash cures.